Global Blockbuster Drugs Market 2015 - 2025: Top 50 Drugs Analysis, Deal Trends, Players and Forecasts

December 2018 | 180 pages | ID: G4DCA6C9855EN
DPI Research

Abstracts

The global 50 blockbuster drugs market size is estimated to reach a value of US$ 292 billion by 2025.

'Global Blockbuster Drugs Market 2015 - 2025: Top 50 Drugs Analysis, Deal Trends, Players and Forecasts' presents an in-depth assessment of the global blockbuster drugs market dynamics, opportunities, future roadmap, competitive landscape and discusses major trends. The report offers the most up-to-date industry data on the actual market situation and future outlook for global blockbuster drugs market. The report includes historic data from 2015 to 2017 and forecasts until 2025.

The report contains a granular analysis of the present industry situations, market demands, reveals facts on the market size, revenues and provides forecasts through 2025. The report provides clear insight into current and future developments of the global blockbuster drugs market. The report explores detailed analysis of top 50 drugs market assessment globally from 2015 to 2017 and forecasts to 2025. The report also details the latest information about the global research & development spend by pharma & biotech companies

Additionally, the report includes assessment of most valuable drugs research and development projects insights by phase and market value. Key trends in terms of collaboration, merger & acquisition, partnerships and licensing agreement are analyzed with details. The report also explores detailed description of growth drivers and inhibitors of the global blockbuster drugs market.

The report concludes with the profiles of major players in the global blockbuster drugs market. The key market players are evaluated on various parameters such as business overview and recent development.

The Major Companies Dominating this Market for its Products, Services and Continuous Product Developments are:

1) AbbVie
2) Celgene
3) Gilead Science
4) Merck
5) Roche
6) Bristol–Myers Squibb
7) Pfizer
8) Johnson & Johnson
9) Amgen
10) Biogen
11) Bayer
12) Regeneron Pharmaceuticals
13) Novo Nordisk
14) Allergan
15) Alexion Pharmaceuticals
16) GlaxoSmithKline
17) Novartis
18) Eli Lilly and Company
19) Astrazeneca
20) Incyte Corporation
21) Boehringer Ingelheim
22) Astellas Pharma

Top 50 Blockbuster Drugs Covered Under This Report Are:

1) Humira
2) Imbruvica
3) Revlimid
4) Genvoya
5) Truvada
6) Harvoni
7) Epclusa
8) Keytruda
9) Januvia/Janumet
10) Herceptin
11) Avastin
12) MabThera/Rituxan
13) Perjeta
14) Opdivo
15) Eliquis
16) Orencia
17) Sprycel
18) Lyrica
19) Ibrance
20) Simponi
21) Stelara
22) Zytiga
23) Invega Sustenna
24) Xarelto
25) Enbrel
26) Tagrisso
27) Tecfidera
28) Eylea
29) Victoza
30) Botox
31) Soliris
32) Triumeq
33) Seretide/Advair
34) Gilenya
35) Cosentyx
36) Trulicity
37) Cialis
38) Humalog
39) Symbicort
40) Zepatier
41) Pomalyst/Imnovid
42) Darzalex
43) Prolia/Xgeva
44) Ocrevus
45) Xtandi
46) Tivicay
47) Jakafi/Jakavi
48) Jardiance
49) Trajenta/Jentadueto
50) Relvar/Breo Ellipta

The Latest Industry Data Included in this Report:

• Global Top 50 Blockbuster Drugs Market Size & Analysis (2015 – 2025)
• Global Top 50 Blockbuster Drugs Market Share & Y–o–Y Growth (%), 2015 – 2025
• Global Top 50 Blockbuster Drugs Market Assessment & Opportunity, (2015 – 2025)
• Most Valuable Drugs Research and Development (R&D) Projects Insights by Phase and Market Value
• Global Research & Development (R&D) Spend by Pharma & Biotech Companies (2015 – 2025)
• Major Deals (Mergers, Acquisitions, Key Agreements, Partnerships & Collaborations)
• Key Market Drivers and Inhibitors of the Global Blockbuster Drugs Market
• Major Companies Analysis

The Answers to the Following Key Questions can be found in the Report:

• What is the size of the global top 50 blockbuster drugs market during 2015 -2025?
• What will be the revenue generated by each drug during the forecast period?
• Which major drugs provides highest market share?
• How are the overall market and major drugs growing?
• What are the key drivers and inhibitors in the current market?
• What will be the impact of drivers and inhibitors in the future?
• How is the market predicted to develop in the future?
• Who are the key players in this market space?

Contents

1. EXECUTIVE SUMMARY

2. GLOBAL TOP 50 BLOCKBUSTER DRUGS MARKET SIZE& ANALYSIS (2015 – 2025)

3. GLOBAL TOP 50 BLOCKBUSTER DRUGS MARKET SHARE & Y–O–Y GROWTH (%), 2015 – 2025

4. KEY DRIVERS AND INHIBITORS OF THE GLOBAL BLOCKBUSTER DRUGS MARKET

4.1 Market Drivers
4.2 Market Inhibitors

5. GLOBAL TOP 50 BLOCKBUSTER DRUGS MARKET ASSESSMENT & OPPORTUNITY, (2015 – 2025)

5.1 Humira (Adalimumab)
5.2 Imbruvica (Ibrutinib)
5.3 Revlimid (Lenalidomide)
5.4 Pomalyst/Imnovid (Pomalidomide)
5.5 Genvoya (Cobicistat; Elvitegravir; Emtricitabine; Tenofovir Alafenamide fumarate)
5.6 Truvada (Emtricitabine/Tenofovir)
5.7 Harvoni (Ledipasvir/Sofosbuvir)
5.8 Epclusa (Sofosbuvir/Velpatasvir)
5.9 Keytruda (Pembrolizumab)
5.10 Januvia/Janumet (Sitagliptin/Metformin)
5.11 Herceptin (Trastuzumab)
5.12 Avastin (Bevacizumab)
5.13 MabThera/Rituxan (Rituximab)
5.14 Perjeta (Pertuzumab)
5.15 Opdivo (Nivolumab)
5.16 Eliquis (Apixaban)
5.17 Orencia (Abatacept)
5.18 Sprycel (Dasatinib)
5.19 Lyrica (Pregabalin)
5.20 Ibrance (Palbociclib)
5.21 Simponi (Golimumab)
5.22 Stelara (Ustekinumab)
5.23 Zytiga (Abiraterone acetate)
5.24 Invega Sustenna (Paliperidone)
5.25 Xarelto (Rivaroxaban)
5.26 Tagrisso (Osimertinib)
5.27 Enbrel (Etanercept)
5.28 Eylea (Aflibercept)
5.29 Victoza (Liraglutide)
5.30 Botox (Botulinum toxin)
5.31 Soliris (Eculizumab)
5.32 Triumeq (Abacavir/Dolutegravir/Lamivudine)
5.33 Seretide/Advair (Fluticasone propionate/Salmeterol)
5.34 Gilenya (Fingolimod)
5.35 Cosentyx (Secukinumab)
5.36 Trulicity (Dulaglutide)
5.37 Humalog (Insulin Lispro)
5.38 Cialis (Tadalafil)
5.39 Symbicort (Budesonide/Formoterol)
5.40 Zapatier (Elbasvir/Grazoprevir)
5.41 Tecfidera (Dimethyl fumarate)
5.42 Darzalex (Daratumumab)
5.43 Prolia/Xgeva (Denosumab)
5.44 Ocrevus (Ocrelizumab)
5.45 Xtandi (Enzalutamide)
5.46 Tivicay (Dolutegravir)
5.47 Jakafi/Jakavi (Ruxolitinib Phosphate)
5.48 Jardiance (Empagliflozin)
5.49 Trajenta/Jentadueto (Linagliptin)
5.50 Relvar/Breo Ellipta (Fluticasone furoate/Vilanterol)

6. MOST VALUABLE DRUGS RESEARCH AND DEVELOPMENT (R&D) PROJECTS INSIGHTS BY PHASE AND MARKET VALUE

7. GLOBAL RESEARCH & DEVELOPMENT (R&D) SPEND BY PHARMA & BIOTECH COMPANIES (2015 – 2025)

8. MAJOR DEALS (MERGERS, ACQUISITIONS, KEY AGREEMENTS, PARTNERSHIPS & COLLABORATIONS)

9. KEY COMPANIES ANALYSIS

9.1 AbbVie
  9.1.1 Business Overview
  9.1.2 Recent Development
9.2 Celgene
  9.2.1 Business Overview
  9.2.2 Recent Development
9.3 Gilead Science
  9.3.1 Business Overview
  9.3.2 Recent Development
9.4 Merck
  9.4.1 Business Overview
  9.4.2 Recent Development
9.5 Roche
  9.5.1 Business Overview
  9.5.2 Recent Development
9.6 Bristol–Myers Squibb
  9.6.1 Business Overview
  9.6.2 Recent Development
9.7 Pfizer
  9.7.1 Business Overview
  9.7.2 Recent Development
9.8 Johnson & Johnson
  9.8.1 Business Overview
  9.8.2 Recent Development
9.9 Amgen
  9.9.1 Business Overview
  9.9.2 Recent Development
9.10 Biogen
  9.10.1 Business Overview
  9.10.2 Recent Development
9.11 Bayer
  9.11.1 Business Overview
  9.11.2 Recent Development
9.12 Regeneron Pharmaceuticals
  9.12.1 Business Overview
  9.12.2 Recent Development
9.13 Novo Nordisk
  9.13.1 Business Overview
  9.13.2 Recent Development
9.14 Allergan
  9.14.1 Business Overview
  9.14.2 Recent Development
9.15 Alexion pharmaceuticals
  9.15.1 Business Overview
  9.15.2 Recent Development
9.16 GlaxoSmithKline
  9.16.1 Business Overview
  9.16.2 Recent Development
9.17 Novartis
  9.17.1 Business Overview
  9.17.2 Recent Development
9.18 Eli Lilly and Company
  9.18.1 Business Overview
  9.18.2 Recent Development
9.19 Astrazeneca
  9.19.1 Business Overview
  9.19.2 Recent Development
9.20 Incyte Corporation
  9.20.1 Business Overview
  9.20.2 Recent Development
9.21 Boehringer Ingelheim
  9.21.1 Business Overview
  9.21.2 Recent Development
9.22 Astellas Pharma
  9.22.1 Business Overview
  9.22.2 Recent Development

List Of Tables

LIST OF TABLES

Table 3–1: Global Top 50 Blockbuster Drugs Market Share & Y–o–Y Growth (%), 2015 – 2017
Table 3–2: Global Top 50 Blockbuster Drugs Market Share & Y–o–Y Growth Forecast (%), 2018 – 2025
Table 6–1: Most Valuable Drugs R&D Projects Insights by Phase and Market Value
Table 8–1: Collaboration Deals
Table 8–2: Merger and Acquisitions
Table 8–3: Licensing Agreement
Table 8–4: Partnership Deals

List Of Figures

LIST OF FIGURES

Figure 2–1: Global Top 50 Blockbuster Drugs Market Siz (Billion US$), 2015 – 2017
Figure 2–2: Global Top 50 Blockbuster Drugs Market Size Forecast (Billion US$), 2018 – 2025
Figure 5–1: Global Humira Market Value (Million US$), 2015 – 2017
Figure 5–2: Global Humira Market Value Forecast (Million US$), 2018 – 2025
Figure 5–3: Global Imbruvica Market Value (Million US$), 2015 – 2017
Figure 5–4: Global Imbruvica Market Value Forecast (Million US$), 2018 – 2025
Figure 5–5: Global Revlimid Market Value (Million US$), 2015 – 2017
Figure 5–6: Global Revlimid Market Value Forecast (Million US$), 2018 – 2025
Figure 5–7: Global Pomalyst/Imnovid Market Value (Million US$), 2015 – 2017
Figure 5–8: Global Pomalyst/Imnovid Market Value Forecast (Million US$), 2018 – 2025
Figure 5–9: Global Genvoya Market Value (Million US$), 2015 – 2017
Figure 5–10: Global Genvoya Market Value Forecast (Million US$), 2018 – 2025
Figure 5–11: Global Truvada Market Value (Million US$), 2015 – 2017
Figure 5–12: Global Truvada Market Value Forecast (Million US$), 2018 – 2025
Figure 5–13: Global Harvoni Market Value (Million US$), 2015 – 2017
Figure 5–14: Global Harvoni Market Value Forecast (Million US$), 2018 – 2025
Figure 5–15: Global Epclusa Market Value (Million US$), 2015 – 2017
Figure 5–16: Global Epclusa Market Value Forecast (Million US$), 2018 – 2025
Figure 5–17: Global Keytruda Market Value (Million US$), 2015 – 2017
Figure 5–18: Global Keytruda Market Value Forecast (Million US$), 2018 – 2025
Figure 5–19: Global Januvia/Janumet Market Value (Million US$), 2015 – 2017
Figure 5–20: Global Januvia/Janumet Market Value Forecast (Million US$), 2018 – 2025
Figure 5–21: Global Herceptin Market Value (Million US$), 2015 – 2017
Figure 5–22: Global Herceptin Market Value Forecast (Million US$), 2018 – 2025
Figure 5–23: Global Avastin Market Value (Million US$), 2015 – 2017
Figure 5–24: Global Avastin Market Value Forecast (Million US$), 2018 – 2025
Figure 5–25: Global MabThera/Rituxan Market Value (Million US$), 2015 – 2017
Figure 5–26: Global MabThera/Rituxan Market Value Forecast (Million US$), 2018 – 2025
Figure 5–27: Global Perjeta Market Value (Million US$), 2015 – 2017
Figure 5–28: Global Perjeta Market Value Forecast (Million US$), 2018 – 2025
Figure 5–29: Global Opdivo Market Value (Million US$), 2015 – 2017
Figure 5–30: Global Opdivo Market Value Forecast (Million US$), 2018 – 2025
Figure 5–31: Global Eliquis Market Value (Million US$), 2015 – 2017
Figure 5–32: Global Eliquis Market Value Forecast (Million US$), 2018 – 2025
Figure 5–33: Global Orencia Market Value (Million US$), 2015 – 2017
Figure 5–34: Global Orencia Market Value Forecast (Million US$), 2018 – 2025
Figure 5–35: Global Sprycel Market Value (Million US$), 2015 – 2017
Figure 5–36: Global Sprycel Market Value Forecast (Million US$), 2018 – 2025
Figure 5–37: Global Lyrica Market Value (Million US$), 2015 – 2017
Figure 5–38: Global Lyrica Market Value Forecast (Million US$), 2018 – 2025
Figure 5–39: Global Ibrance Market Value (Million US$), 2015 – 2017
Figure 5–40: Global Ibrance Market Value Forecast (Million US$), 2018 – 2025
Figure 5–41: Global Simponi Market Value (Million US$), 2015 – 2017
Figure 5–42: Global Simponi Market Value Forecast (Million US$), 2018 – 2025
Figure 5–43: Global Stelara Market Value (Million US$), 2015 – 2017
Figure 5–44: Global Stelara Market Value Forecast (Million US$), 2018 – 2025
Figure 5–45: Global Zytiga Market Value (Million US$), 2015 – 2017
Figure 5–46: Global Zytiga Market Value Forecast (Million US$), 2018 – 2025
Figure 5–47: Global Invega Sustenna Market Value (Million US$), 2015 – 2017
Figure 5–48: Global Invega Sustenna Market Value Forecast (Million US$), 2018 – 2025
Figure 5–49: Global Xarelto Market Value (Million US$), 2015 – 2017
Figure 5–50: Global Xarelto Market Value Forecast (Million US$), 2018 – 2025
Figure 5–51: Global Tagrisso Market Value (Million US$), 2015 – 2017
Figure 5–52: Global Tagrisso Market Value Forecast (Million US$), 2018 – 2025
Figure 5–53: Global Enbrel Market Value (Million US$), 2015 – 2017
Figure 5–54: Global Enbrel Market Value Forecast (Million US$), 2018 – 2025
Figure 5–55: Global Eylea Market Value (Million US$), 2015 – 2017
Figure 5–56: Global Eylea Market Value Forecast (Million US$), 2018 – 2025
Figure 5–57: Global Victoza Market Value (Million US$), 2015 – 2017
Figure 5–58: Global Victoza Market Value Forecast (Million US$), 2018 – 2025
Figure 5–59: Global Botox Market Value (Million US$), 2015 – 2017
Figure 5–60: Global Botox Market Value Forecast (Million US$), 2018 – 2025
Figure 5–61: Global Soliris Market Value (Million US$), 2015 – 2017
Figure 5–62: Global Soliris Market Value Forecast (Million US$), 2018 – 2025
Figure 5–63: Global Triumeq Market Value (Million US$), 2015 – 2017
Figure 5–64: Global Triumeq Market Value Forecast (Million US$), 2018 – 2025
Figure 5–65: Global Seretide/Advair Market Value (Million US$), 2015 – 2017
Figure 5–66: Global Seretide/Advair Market Value Forecast (Million US$), 2018 – 2025
Figure 5–67: Global Gilenya Market Value (Million US$), 2015 – 2017
Figure 5–68: Global Gilenya Market Value Forecast (Million US$), 2018 – 2025
Figure 5–69: Global Cosentyx Market Value (Million US$), 2015 – 2017
Figure 5–70: Global Cosentyx Market Value Forecast (Million US$), 2018 – 2025
Figure 5–71: Global Trulicity Market Value (Million US$), 2015 – 2017
Figure 5–72: Global Trulicity Market Value Forecast (Million US$), 2018 – 2025
Figure 5–73: Global Humalog Market Value (Million US$), 2015 – 2017
Figure 5–74: Global Humalog Market Value Forecast (Million US$), 2018 – 2025
Figure 5–75: Global Cialis Market Value (Million US$), 2015 – 2017
Figure 5–76: Global Cialis Market Value Forecast (Million US$), 2018 – 2025
Figure 5–77: Global Symbicort Market Value (Million US$), 2015 – 2017
Figure 5–78: Global Symbicort Market Value Forecast (Million US$), 2018 – 2025
Figure 5–79: Global Zapatier Market Value (Million US$), 2015 – 2017
Figure 5–80: Global Zapatier Market Value Forecast (Million US$), 2018 – 2025
Figure 5–81: Global Tacfidera Market Value (Million US$), 2015 – 2017
Figure 5–82: Global Tacfidera Market Value Forecast (Million US$), 2018 – 2025
Figure 5–83: Global Darzalex Market Value (Million US$), 2015 – 2017
Figure 5–84: Global Darzalex Market Value Forecast (Million US$), 2018 – 2025
Figure 5–85: Global Prolia/Xgeva Market Value (Million US$), 2015 – 2017
Figure 5–86: Global Prolia/Xgeva Market Value Forecast (Million US$), 2018 – 2025
Figure 5–87: Global Ocrevus Market & Forecast Value (Million US$), 2017 – 2025
Figure 5–88: Global Xtandi Market Value (Million US$), 2015 – 2017
Figure 5–89: Global Xtandi Market Value Forecast (Million US$), 2018 – 2025
Figure 5–90: Global Tivicay Market Value (Million US$), 2015 – 2017
Figure 5–91: Global Tivicay Market Value Forecast (Million US$), 2018 – 2025
Figure 5–92: Global Jakafi/Jakavi Market Value (Million US$), 2015 – 2017
Figure 5–93: Global Jakafi/Jakavi Market Value Forecast (Million US$), 2018 – 2025
Figure 5–94: Global Jardiance Market Value (Million US$), 2015 – 2017
Figure 5–95: Global Jardiance Market Value Forecast (Million US$), 2018 – 2025
Figure 5–96: Global Trajenta/Jentadueto Market Value (Million US$), 2015 – 2017
Figure 5–97: Global Trajenta/Jentadueto Market Value Forecast (Million US$), 2018 – 2025
Figure 5–98: Global Relvar/Breo Ellipta Market Value (Million US$), 2015 – 2017
Figure 5–99: Global Relvar/Breo Ellipta Market Value Forecast (Million US$), 2018 – 2025
Figure 7–1: Global R&D Spend by Pharma & Biotech Companies, 2015 – 2025